NCT05342493 Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use
| NCT ID | NCT05342493 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Otsuka Pharmaceutical Co., Ltd. |
| Condition | Migraine Disorders |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2022-04-20 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2022-04-20 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the long-term safety of AJOVY in patients under actual use conditions and to specifically evaluate cardiovascular events. In addition, information on efficacy will be collected.
Eligibility Criteria
Inclusion Criteria: \- Exclusion Criteria: * patients with a known hypersensitivity to components of AJOVY
Contact & Investigator
Pharmacovigilance Department Otsuka Pharmaceutical Co., Ltd
✉ komaniwa.satoshi@otsuka.jp📞 +81-6-6943-7722
Yasuhiko Fukuta, PhD
STUDY DIRECTOR
Otsuka Pharmaceutical Co., Ltd.
Frequently Asked Questions
Who can join the NCT05342493 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Migraine Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05342493 currently recruiting?
Yes, NCT05342493 is actively recruiting participants. Contact the research team at komaniwa.satoshi@otsuka.jp for enrollment information.
Where is the NCT05342493 trial being conducted?
This trial is being conducted at Osaka, Japan.
Who is sponsoring the NCT05342493 clinical trial?
NCT05342493 is sponsored by Otsuka Pharmaceutical Co., Ltd.. The principal investigator is Yasuhiko Fukuta, PhD at Otsuka Pharmaceutical Co., Ltd.. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.